Silexion Therapeutics Corp
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Silexion Therapeutics Corp | |
|---|---|
| By: | /s/ Ilan Hadar |
| Name: | Ilan Hadar |
| Title: | Chairman of the Board and Chief Executive Officer |
| Date: | March 17, 2026 |
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Position | Date |
|---|---|---|
| /s/ Ilan Hadar | Chairman of the Board and Chief Executive Officer | March 17, 2026 |
| Ilan Hadar | (Principal Executive Officer) | |
| /s/ Mirit Horenshtein Hadar | Chief Financial Officer | March 17, 2026 |
| Mirit Horenshtein Hadar | (Principal Financial and Accounting Officer) | |
| /s/ Ruth Alon | Director | March 17, 2026 |
| Ruth Alon | ||
| /s/ Dror Abramov | Director | March 17, 2026 |
| Dror Abramov | ||
| /s/ Ilan Levin | Director | March 17, 2026 |
| Ilan Levin | ||
| /s/ Avner Lushi | Director | March 17, 2026 |
| Avner Lushi | ||
| /s/ Shlomo Noy | Director | March 17, 2026 |
| Shlomo Noy | ||
| /s/ Amnon Peled | Director | March 17, 2026 |
| Amnon Peled | ||
CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2025
CONSOLIDATED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2025
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.